July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
3 citations
,
May 2016 in “Dermatopathology” Lrig1 could be a marker for advanced sebaceous carcinoma.
July 2021 in “Plastic and reconstructive surgery. Global open” Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.
June 2025 in “Clinical Cosmetic and Investigational Dermatology” There's an urgent need for better treatments for hair loss caused by radiation therapy.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
100 citations
,
October 2006 in “Rapid Communications in Mass Spectrometry” A quick method effectively detects banned substances in urine.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
5 citations
,
June 2017 in “BJU international” Pregnant female urologists should avoid certain drugs and use protective measures to stay safe.
October 2014 in “Cancer Research” A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
January 2026 in “Regenerative Biomaterials” Advanced hydrogels can autonomously deliver drugs to treat radiation skin injuries, but challenges remain for clinical use.
January 2024 in “Wiadomości Lekarskie” Thyroid disorders, especially autoimmune ones, are very common in the studied group.
3 citations
,
January 2024 in “Liver International” Targeting thyroid hormone receptor α in liver cells may help treat liver fibrosis.
April 2018 in “Radiotherapy and Oncology” Mitochondria may influence how cells respond to radiation, affecting nearby non-irradiated cells.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
June 2025 in “JCEM Case Reports” False high testosterone levels were corrected using a more accurate test.
January 2017 in “NASA Technical Reports Server (NASA)” Early changes in skin gene expression can predict later bone mass loss after radiation exposure.
3 citations
,
April 2020 in “Clinical endocrinology and metabolism journal” Imaging helps detect adrenal gland issues and monitor treatment in congenital adrenal hyperplasia, and can identify tumors affecting fertility.
October 2004 in “Radiotherapy and oncology” Active vitamin D3 might protect hair follicles from radiation damage.
227 citations
,
January 1998 in “Journal of biological chemistry/The Journal of biological chemistry” Mutations at Val-889 and Arg-752 disrupt key interactions in the androgen receptor, affecting its function.
February 2024 in “Folia Medica” Platelet-rich plasma treatment is effective for hair loss in patients regardless of their thyroid antibody levels.
50 citations
,
July 2018 in “Psychoneuroendocrinology” Hair cortisol can indicate long-term stress levels, but hair growth rate differences may affect accuracy.
57 citations
,
May 2014 in “Molecular Phylogenetics and Evolution” The research found how GPCR Class A Rhodopsin receptors are related and suggested possible substances they interact with.
January 2025 in “Mansoura Medical Journal” TPO antibodies can help identify hypothyroid patients who still have symptoms despite normal TSH levels.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.